Start Over

Impact of the UK lockdown on people at risk of COPD.

Authors :: Donaldson GC
Ritchie AI
Calverley PMA
Vestbo J
Fageras M
de la Hoz A
Bucchioni E
Compton CH
Mezzi K
Wedzicha JA
Source :: ERJ open research [ERJ Open Res] 2021 Nov 22; Vol. 7 (4). Date of Electronic Publication: 2021 Nov 22 (Print Publication: 2021).
Publication Year :: 2021
Abstract: Impact of the UK lockdown on early COPD https://bit.ly/3laMsmi.<br />Competing Interests: Conflict of interest: G.C. Donaldson reports grants from AstraZeneca, and personal fees from AstraZeneca, the American Thoracic Society, FWO Flanders and Novartis, outside the submitted work. Conflict of interest: A.I. Ritchie has nothing to disclose. Conflict of interest: P.M.A. Calverley reports grants and personal fees from GlaxoSmithKline, personal fees from AstraZeneca, Boehringer Ingelheim, Phillips Respironics, Novartis, Recipharm and Zambon, and personal fees and nonfinancial support from Boehringer Ingelheim outside the submitted work. Conflict of interest: J. Vestbo reports personal fees from AstraZeneca and Boehringer Ingelheim, grants from Boehringer Ingelheim, and personal fees from Chiesi, GSK, Novartis and TEVA, outside the submitted work. Conflict of interest: M. Fageras has nothing to disclose. Conflict of interest: A. de la Hoz reports a salary from Boehringer Ingelheim International. Conflict of interest: E. Bucchioni is an employee of Chiesi. Conflict of interest: C.H. Compton is an employee of and holds shares in GSK. Conflict of interest: K. Mezzi is a Novartis Pharma AG employee. Conflict of interest: J.A. Wedzicha reports grants from GSK, meeting expenses only (no personal fees since January 2015) from Novartis, Boehringer Ingelheim and AstraZeneca, and a grant from Chiesi outside the submitted work.<br /> (Copyright ©The authors 2021.)